TERRASCEND CORP (TSND.CA) Stock Fundamental Analysis
TSX:TSND - Toronto Stock Exchange - CA88105E1088 - Common Stock - Currency: CAD
TSND gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 34 industry peers in the Pharmaceuticals industry. TSND may be in some trouble as it scores bad on both profitability and health. TSND is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
TSND had negative earnings in the past year.
In the past year TSND had a positive cash flow from operations.
In the past 5 years TSND reported 4 times negative net income.
The reported operating cash flow has been mixed in the past 5 years: TSND reported negative operating cash flow in multiple years.
1.2 Ratios
Looking at the Return On Assets, with a value of -13.21%, TSND is in line with its industry, outperforming 44.12% of the companies in the same industry.
With a Return On Equity value of -45.34%, TSND perfoms like the industry average, outperforming 41.18% of the companies in the same industry.
With a decent Return On Invested Capital value of 3.89%, TSND is doing good in the industry, outperforming 76.47% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -13.21% | ||
| ROE | -45.34% | ||
| ROIC | 3.89% |
ROA(3y)-24.86%
ROA(5y)-21.32%
ROE(3y)-62.74%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With a decent Operating Margin value of 9.32%, TSND is doing good in the industry, outperforming 73.53% of the companies in the same industry.
In the last couple of years the Operating Margin of TSND has declined.
TSND has a better Gross Margin (48.90%) than 64.71% of its industry peers.
In the last couple of years the Gross Margin of TSND has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 9.32% | ||
| PM (TTM) | N/A | ||
| GM | 48.9% |
OM growth 3Y-5.82%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.82%
GM growth 5Y37.79%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so TSND is destroying value.
TSND has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, TSND has more shares outstanding
Compared to 1 year ago, TSND has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -0.92, we must say that TSND is in the distress zone and has some risk of bankruptcy.
TSND has a Altman-Z score (-0.92) which is comparable to the rest of the industry.
The Debt to FCF ratio of TSND is 7.34, which is on the high side as it means it would take TSND, 7.34 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of TSND (7.34) is better than 70.59% of its industry peers.
A Debt/Equity ratio of 1.09 is on the high side and indicates that TSND has dependencies on debt financing.
TSND has a Debt to Equity ratio of 1.09. This is amonst the worse of the industry: TSND underperforms 82.35% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.09 | ||
| Debt/FCF | 7.34 | ||
| Altman-Z | -0.92 |
ROIC/WACC0.37
WACC10.65%
2.3 Liquidity
TSND has a Current Ratio of 1.33. This is a normal value and indicates that TSND is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.33, TSND perfoms like the industry average, outperforming 44.12% of the companies in the same industry.
TSND has a Quick Ratio of 1.33. This is a bad value and indicates that TSND is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.71, TSND is not doing good in the industry: 64.71% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.33 | ||
| Quick Ratio | 0.71 |
3. Growth
3.1 Past
TSND shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 18.18%, which is quite good.
The Revenue has decreased by -3.36% in the past year.
Measured over the past years, TSND shows a very strong growth in Revenue. The Revenue has been growing by 36.80% on average per year.
EPS 1Y (TTM)18.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%31.25%
Revenue 1Y (TTM)-3.36%
Revenue growth 3Y13.38%
Revenue growth 5Y36.8%
Sales Q2Q%-14.11%
3.2 Future
TSND is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.08% yearly.
Based on estimates for the next years, TSND will show a small growth in Revenue. The Revenue will grow by 5.52% on average per year.
EPS Next Y61.47%
EPS Next 2Y28.11%
EPS Next 3Y20.17%
EPS Next 5Y13.08%
Revenue Next Year2.71%
Revenue Next 2Y10.42%
Revenue Next 3Y12.82%
Revenue Next 5Y5.52%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
TSND reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TSND. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
TSND's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. TSND is cheaper than 91.18% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, TSND is valued cheaply inside the industry as 88.24% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 4.31 | ||
| EV/EBITDA | 5.61 |
4.3 Compensation for Growth
TSND's earnings are expected to grow with 20.17% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.11%
EPS Next 3Y20.17%
5. Dividend
5.1 Amount
TSND does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX:TSND (4/25/2025, 7:00:00 PM)
0.46
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners36.02%
Inst Owner ChangeN/A
Ins Owners3.14%
Ins Owner ChangeN/A
Market Cap163.82M
Analysts80
Price Target2.55 (454.35%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-170.04%
Min EPS beat(2)-259.48%
Max EPS beat(2)-80.6%
EPS beat(4)0
Avg EPS beat(4)-121.63%
Min EPS beat(4)-259.48%
Max EPS beat(4)-17.65%
EPS beat(8)0
Avg EPS beat(8)-214.72%
EPS beat(12)2
Avg EPS beat(12)-334.6%
EPS beat(16)3
Avg EPS beat(16)-347.63%
Revenue beat(2)0
Avg Revenue beat(2)-4.01%
Min Revenue beat(2)-5.43%
Max Revenue beat(2)-2.6%
Revenue beat(4)0
Avg Revenue beat(4)-4.24%
Min Revenue beat(4)-6.01%
Max Revenue beat(4)-2.6%
Revenue beat(8)2
Avg Revenue beat(8)-2.32%
Revenue beat(12)2
Avg Revenue beat(12)-5.28%
Revenue beat(16)2
Avg Revenue beat(16)-6.35%
PT rev (1m)-12.66%
PT rev (3m)-19.68%
EPS NQ rev (1m)0%
EPS NQ rev (3m)18.75%
EPS NY rev (1m)8.93%
EPS NY rev (3m)-2%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.13%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.29%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.39 | ||
| P/FCF | 4.31 | ||
| P/OCF | 3.11 | ||
| P/B | 0.67 | ||
| P/tB | N/A | ||
| EV/EBITDA | 5.61 |
EPS(TTM)-0.37
EYN/A
EPS(NY)-0.14
Fwd EYN/A
FCF(TTM)0.11
FCFY23.18%
OCF(TTM)0.15
OCFY32.11%
SpS1.19
BVpS0.69
TBVpS-0.39
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -13.21% | ||
| ROE | -45.34% | ||
| ROCE | 5.41% | ||
| ROIC | 3.89% | ||
| ROICexc | 4.11% | ||
| ROICexgc | 9.19% | ||
| OM | 9.32% | ||
| PM (TTM) | N/A | ||
| GM | 48.9% | ||
| FCFM | 8.93% |
ROA(3y)-24.86%
ROA(5y)-21.32%
ROE(3y)-62.74%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y-2.11%
ROICexcg growth 5YN/A
ROICexc growth 3Y1.66%
ROICexc growth 5YN/A
OM growth 3Y-5.82%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.82%
GM growth 5Y37.79%
F-Score6
Asset Turnover0.51
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.09 | ||
| Debt/FCF | 7.34 | ||
| Debt/EBITDA | 3.73 | ||
| Cap/Depr | 45.9% | ||
| Cap/Sales | 3.44% | ||
| Interest Coverage | 1.2 | ||
| Cash Conversion | 73.58% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.33 | ||
| Quick Ratio | 0.71 | ||
| Altman-Z | -0.92 |
F-Score6
WACC10.65%
ROIC/WACC0.37
Cap/Depr(3y)90.87%
Cap/Depr(5y)192.32%
Cap/Sales(3y)7.77%
Cap/Sales(5y)14.52%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)18.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%31.25%
EPS Next Y61.47%
EPS Next 2Y28.11%
EPS Next 3Y20.17%
EPS Next 5Y13.08%
Revenue 1Y (TTM)-3.36%
Revenue growth 3Y13.38%
Revenue growth 5Y36.8%
Sales Q2Q%-14.11%
Revenue Next Year2.71%
Revenue Next 2Y10.42%
Revenue Next 3Y12.82%
Revenue Next 5Y5.52%
EBIT growth 1Y-18.49%
EBIT growth 3Y6.79%
EBIT growth 5YN/A
EBIT Next Year150.61%
EBIT Next 3Y49.96%
EBIT Next 5Y32.69%
FCF growth 1Y51.87%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y38.15%
OCF growth 3YN/A
OCF growth 5YN/A